The Journal of Organic Chemistry
Article
158.3, 137.1, 134.1, 128.5, 128.2, 127.9, 127.5, 127.5, 114.4, 76.1, 74.9,
70.0, 63.7, 25.9, 25.8, 18.3, 18.1, −4.6, −5.1, −5.3. HRMS (DART-
TOF): calcd for C22H31O3Si+ (M − OTBS)+, 371.20370; found,
114.5, 113.9, 109.7, 84.8, 74.4, 70.0, 62.5, 55.7, 25.7, 25.6, 18.13, 18.05,
−5.0, −5.2, −5.6. HRMS (DART-TOF): calcd for C36H53O6Si2+ (M +
25
H)+, 637.33752; found, 637.33654. [α]D +18.8 (c 1.00, CHCl3).
25
371.20343. [α]D +31.2 (c 1.00, CHCl3).
The opposite enantiomer, 4-(((5R,6R)-5-(4-(benzyloxy)phenyl)-
The opposite enantiomer, (5R,6S)-5-(4-(benzyloxy)phenyl)-
2,2,3,3,9,9,10,10-octamethyl-4,8-dioxa-3,9-disilaundecan-6-yl)oxy)-3-
methoxybenzaldehyde, provides a specific rotation of [α]D −17.4 (c
1.00, CHCl3).
25
2,2,3,3,9,9,10,10-octamethyl-4,8-dioxa-3,9-disilaundecan-6-ol, provides
25
a specific rotation of [α]D −30.7 (c 1.00, CHCl3).
(5S,6R)-5-(4-(Benzyloxy)-3,5-dimethoxyphenyl)-2,2,3,3,9,9,10,10-
octamethyl-4,8-dioxa-3,9-disilaundecan-6-ol (8c). Following the
general procedure outlined above for compound 8a, (2R,3S)-3-(4-
(benzyloxy)-3,5-dimethoxyphenyl)-3-((tert-butyldimethylsilyl)oxy)-
propane-1,2-diol (7c) (1.4 g, 3.1 mmol) was converted to yield 1.68 g
of the protected asymmetric alcohol 8c (96.7%) as a colorless oil. IR
(neat): 3517.93, 2953.75, 2928.51, 2856.42, 1462.2, 1251.07, 834.83,
671.17 cm−1. 1H NMR (500 MHz, CDCl3): δ 7.61 (d, J = 6.8 Hz, 2H),
7.47 (t, J = 7.2 Hz, 2H), 7.44−7.40 (m, 1H), 6.72 (s, 2H), 5.16 (s,
2H), 4.71 (d, J = 5.5 Hz, 1H), 3.95 (s, 6H), 3.88−3.79 (m, 3H), 1.06
(s, 9H), 1.03 (s, 9H), 0.22 (d, J = 3.9 Hz, 6H), 0.19 (s, 3H), −0.00 (s,
3H). 13C NMR (125 MHz, CDCl3): δ 153.2, 137.9, 137.5, 135.9,
128.5, 128.0, 127.7, 103.9, 76.0, 75.4, 74.9, 63.6, 56.0, 25.9, 18.2, −4.7,
−5.1, −5.3. HRMS (DART-TOF): calcd for C24H35O5Si+ (M −
OTBS)+, 431.22483; found, 431.22634. [α]D25 +25.7 (c 1.00, CHCl3).
The opposite enantiomer, (5R,6S)-5-(4-(benzyloxy)-3,5-dimethoxy-
phenyl)-2,2,3,3,9,9,10,10-octamethyl-4,8-dioxa-3,9-disilaundecan-6-ol,
4-(((5S,6S)-5-(4-(Benzyloxy)-3,5-dimethoxyphenyl)-
2,2,3,3,9,9,10,10-octamethyl-4,8-dioxa-3,9-disilaundecan-6-yl)oxy)-
3-methoxybenzaldehyde (9c). Following the general procedure
outlined above for compound 9a, (5S,6R)-5-(4-(benzyloxy)-3,5-
dimethoxyphenyl)-2,2,3,3,9,9,10,10-octamethyl-4,8-dioxa-3,9-disila-un-
decan-6-ol (8c) (1.3 g, 2.3 mmol) was converted to yield 1.04 g of the
intermediate 9c (65%) as a light yellow oil. IR (neat): 2952.25,
2929.26, 2855.95, 1684.02, 1505.49, 1463.28, 1268.19, 697.2 cm−1. 1H
NMR (500 MHz, CDCl3): δ 9.92 (s, 1H), 7.54 (d, J = 6.7 Hz, 2H),
7.49−7.46 (m, 2H), 7.43−7.35 (m, 3H), 7.21 (d, J = 7.9 Hz, 1H), 6.77
(s, 2H), 5.11 (s, 2H), 5.01 (d, J = 6.4 Hz, 1H), 4.58−4.55 (m, 1H),
3.97 (s, 3H), 3.89 (s, 6H), 3.85−3.82 (m, 1H), 3.61 (dd, J = 11.4, 5.6
Hz, 1H), 0.90 (d, J = 16.0 Hz, 20H), 0.06 (d, J = 10.1 Hz, 6H), 0.00
(d, J = 3.6 Hz, 6H). 13C NMR (125 MHz, CDCl3): δ 190.9, 154.5,
153.2, 150.2, 137.7, 136.7, 136.0, 129.8, 128.5, 128.0, 127.7, 126.4,
113.5, 109.6, 104.0, 84.2, 74.8, 74.4, 62.3, 56.0, 55.6, 25.7, 25.6, 18.2,
18.1, −5.0, −5.2, −5.58, −5.61. HRMS (DART-TOF): calcd for
25
C32H41O7Si+ (M − OTBS)+, 565.26161; found, 565.26184. [α]D
25
provides a specific rotation of [α]D −26.8 (c 1.00, CHCl3).
+29.5 (c 1.00, CHCl3).
4-(((5S,6S)-5-(4-(Benzyloxy)-3-methoxyphenyl)-2,2,3,3,9,9,10,10-
octamethyl-4,8-dioxa-3,9-disilaundecan-6-yl)oxy)-3-methoxyben-
zaldehyde (9a). To a solution of THF containing PPh3 (2.8 g, 10.8
mmol) was added diisopropylazodicarboxylate (2.2 mL, 10.8 mmol),
and the mixture was stirred for 30 min. This was followed by the
simultaneous addition of 4-hydroxy-3-methoxybenzaldehyde (1.6 g,
10.8 mmol) and the alcohol intermediate 8a (2.3 g, 4.3 mmol). The
reaction mixture was stirred at rt for 1 h before being refluxed for a
further 3 h. After complete consumption of the starting material, as
monitored by TLC, the organic phase was washed with water (2 × 100
mL), dried over MgSO4, and concentrated in vacuo. The crude
compound was purified by column chromatography using hexane/
acetone (9:1) to afford the intermediate 9a (1.9 g, 2.8 mmol, 65%) as a
light yellow oil. IR (neat): 2953.02, 2928.77, 2855.95, 1683.97,
The opposite enantiomer, 4-(((5R,6R)-5-(4-(benzyloxy)-3,5-dime-
thoxyphenyl)-2,2,3,3,9,9,10,10-octamethyl-4,8-dioxa-3,9-disilaundecan-
6-yl)oxy)-3-methoxybenzaldehyde, provides a specific rotation of
25
[α]D −32.7 (c 1.00, CHCl3).
4-(((1S,2S)-1-(4-(Benzyloxy)-3-methoxyphenyl)-1,3-dihydroxypro-
pan-2-yl)oxy)-3-methoxybenzaldehyde (10a). To a 100 mL round-
bottom flask was added the TBS-protected intermediate 9a (1.4 g, 2.1
mmol) and dissolved in anhydrous THF. The flask was cooled to 0 °C,
and t-butylammonium fluoride (TBAF) (5.3 mL, 5.3 mmol) was
added to the reaction mixture. The resulting solution was warmed to rt
and stirred for 2 h. After complete consumption of the starting
material, as monitored on TLC, the reaction was quenched by the
addition of saturated NH4Cl. The organic phase was extracted with
EtOAc (3 × 100 mL), dried over MgSO4, and concentrated in vacuo.
The crude compound was purified by column chromatography using
DCM/EtOAc (3:2) to afford the asymmetric diol intermediate 10a
(0.78 g, 1.78 mmol, 85.0%) as a white solid. Mp: 117−118 °C. IR
(neat): 3435.15, 2935.72, 2835.93, 1677.69, 1593.32, 1504.38,
1262.33, 1134.84, 652.27 cm−1. 1H NMR (500 MHz, CDCl3): δ
9.78 (s, 1H), 7.34 (dd, J = 7.8, 5.7 Hz, 4H), 7.28 (t, J = 7.4 Hz, 2H),
7.22 (t, J = 7.2 Hz, 1H), 7.12 (d, J = 8.1 Hz, 1H), 6.92 (d, J = 1.4 Hz,
1H), 6.82−6.76 (m, 2H), 5.06 (s, 2H), 4.89 (d, J = 7.3 Hz, 1H), 4.23
(dt, J = 7.8, 4.4 Hz, 1H), 3.85 (s, 3H), 3.79 (s, 3H), 3.61 (dd, J = 12.3,
3.2 Hz, 1H), 3.53 (dd, J = 12.3, 4.6 Hz, 1H), 3.28 (s, 1H), 2.40 (s,
1H). 13C NMR (125 MHz, CDCl3): δ 190.8, 153.4, 151.2, 149.9,
148.2, 137.0, 132.4, 131.8, 128.5, 127.9, 127.2, 126.3, 119.3, 118.0,
113.9, 110.3, 110.1, 87.8, 73.8, 71.0, 61.5, 56.0. HRMS (DART-TOF):
1
1584.92, 1259.2, 1035.52, 835.42, 696.52 cm−1. H NMR (500 MHz,
CDCl3): δ 9.83 (s, 1H), 7.44 (d, J = 7.3 Hz, 2H), 7.40−7.34 (m, 4H),
7.30 (t, J = 7.3 Hz, 1H), 7.13 (d, J = 8.1 Hz, 1H), 7.05 (d, J = 1.4 Hz,
1H), 6.89−6.83 (m, 2H), 5.14 (s, 2H), 4.92 (d, J = 6.5 Hz, 1H), 4.48
(td, J = 6.1, 2.9 Hz, 1H), 3.88 (s, 6H), 3.70 (dd, J = 11.3, 2.9 Hz, 1H),
3.51 (dd, J = 11.3, 5.8 Hz, 1H), 0.81 (s, 9H), 0.77 (s, 9H), −0.05 (d, J
= 8.4 Hz, 6H), −0.11 (d, J = 4.5 Hz, 6H). 13C NMR (125 MHz,
CDCl3): δ 190.9, 154.7, 150.2, 149.4, 147.7, 137.1, 134.2, 129.7, 128.5,
127.8, 127.3, 126.4, 119.1, 113.7, 113.5, 110.7, 109.6, 84.5, 74.3, 71.1,
62.4, 55.9, 55.6, 25.7, 25.6, 18.13, 18.08, −5.0, −5.2, −5.60, −5.62.
+
HRMS (DART-TOF): calcd for C37H55O7Si2 (M + H)+, 667.34808;
25
found, 667.34567. [α]D +37.8 (c 1.00, CHCl3).
The opposite enantiomer, 4-(((5R,6R)-5-(4-(benzyloxy)-3-methox-
yphenyl)-2,2,3,3,9,9,10,10-octamethyl-4,8-dioxa-3,9-disilaundecan-6-
+
25
calcd for C25H27O7 (M + H)+, 439.17513; found, 439.17461. [α]D
25
yl)oxy)-3-methoxybenzaldehyde, provides a specific rotation of [α]D
+88.8 (c 1.00, CHCl3).
The opposite enantiomer, 4-(((1R,2R)-1-(4-(benzyloxy)-3-
−38.6 (c 1.00, CHCl3).
4-(((5S,6S)-5-(4-(Benzyloxy)phenyl)-2,2,3,3,9,9,10,10-octamethyl-
4,8-dioxa-3,9-disilaundecan-6-yl)oxy)-3-methoxybenzaldehyde
(9b). Following the general procedure outlined above for compound
9a, (5S,6R)-5-(4-(benzyloxy)phenyl)-2,2,3,3,9,9,10,10-octamethyl-4,8-
dioxa-3,9-disilaundecan-6-ol (8b) (2.6 g, 5.2 mmol) was converted to
yield 2.1 g of the intermediate 9b (65%) as a light yellow oil. IR
(neat): 2953.25, 2928.28, 2855.97, 1683.92, 1584.61, 2505.51,
methoxyphenyl)-1,3-dihydroxypropan-2-yl)oxy)-3-methoxybenzalde-
25
hyde, provides a specific rotation of [α]D −85.2 (c 1.00, CHCl3).
4-(((1S,2S)-1-(4-(Benzyloxy)phenyl)-1,3-dihydroxypropan-2-yl)-
oxy)-3-methoxy-benzaldehyde (10b). Following the general proce-
dure outlined above for compound 10a, 4-(((5S,6S)-5-(4-(benzyloxy)-
phenyl)-2,2,3,3,9,9,10,10-octamethyl-4,8-dioxa-3,9-disilaundecan-6-yl)-
oxy)-3-methoxybenzaldehyde (9b) (1.7 g, 2.7 mmol) was converted to
yield 0.98 g of the intermediate 10b (89%) as a colorless oil which
solidifies under vacuum. IR (neat): 3431.3, 2928.17, 1682.84, 1585.12,
1
1236.11, 1035.11, 864.3 cm−1. H NMR (500 MHz, CDCl3): δ 9.82
(s, 1H), 7.43 (d, J = 7.3 Hz, 2H), 7.41−7.35 (m, 4H), 7.33 (d, J = 8.6
Hz, 3H), 7.15 (d, J = 8.0 Hz, 1H), 6.94 (d, J = 8.7 Hz, 2H), 5.05 (s,
2H), 4.92 (d, J = 6.9 Hz, 1H), 4.50 (td, J = 6.4, 2.8 Hz, 1H), 3.88 (s,
3H), 3.67 (dd, J = 11.3, 2.8 Hz, 1H), 3.50 (dd, J = 11.3, 5.9 Hz, 1H),
0.79 (s, 9H), 0.74 (s, 9H), −0.05 (s, 3H), −0.08 (s, 3H), −0.11 (s,
3H), −0.14 (s, 3H). 13C NMR (125 MHz, CDCl3): δ 191.0, 158.4,
155.0, 150.3, 137.0, 133.5, 129.7, 128.6, 128.2, 128.0, 127.5, 126.4,
1
1267.3, 1135.35, 1025, 794.92 cm−1. H NMR (500 MHz, CDCl3): δ
9.78 (s, 1H), 7.34 (dd, J = 8.3, 3.3 Hz, 4H), 7.30 (t, J = 7.4 Hz, 2H),
7.28−7.23 (m, 3H), 7.14 (d, J = 8.1 Hz, 1H), 6.89 (d, J = 8.7 Hz, 2H),
4.98 (s, 2H), 4.91 (d, J = 7.6 Hz, 1H), 4.26−4.22 (m, 1H), 3.85 (s,
3H), 3.60 (dd, J = 12.3, 3.1 Hz, 1H), 3.51 (dd, J = 12.3, 4.5 Hz, 1H),
1777
J. Org. Chem. 2015, 80, 1771−1780